Author(s):
Yogesh S. Purkar, Rajendra K. Surawase
Email(s):
yogeshpurkar5074@gmail.com
DOI:
10.52711/0975-4377.2024.00047 
Address:
Yogesh S. Purkar*, Rajendra K. Surawase
Department of Pharmaceutics, Loknete Dr. J. D. Pawar College of Pharmacy, Manur, Tal. - Kalwan, Dist. - Nashik 423501, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 4,
Year - 2024
ABSTRACT:
Purpose: Extended-release tablets function somewhat like modified-release medications in that their active ingredient is released slowly over a predetermined length of time. Extended-release tablets deliver a drug to the body gradually, guaranteeing a longer therapeutic effect than immediate-release tablets, which offer quick absorption. With their "ER" or "XR" markings, these tablets are designed to keep medication levels constant for extended periods of time. People who might not react well to immediate-release drugs are advised to take them, which are usually taken once daily. Method: The use Wet granulation process can be utilizing for manufacturing extended-release tablet utilizing polymer such as HPMC K100, HPMC K15 and Ethyl cellulose. Result: FTIR analysis indicated no interaction between the medication and its excipients. The developed ER tablet using the wet granulation process. The developed extended-release tablet ranges in weight variation from 250-256mg. It was discovered that the friability 0.32 to 1.32%. The swelling index optimized batch was 85.01%. The drug optimised batch had a 98.94% in vitro release rate. Conclusion: A combination of HPMC K100, HPMC K15, and ethyl cellulose was effectively employed in the creation of Quetiapine fumarate extended-release matrix tablets. The examined extended-release matrix tablet produced optimal smooth blood levels of quetiapine fumarate for a full day and shown a strong in vitro and in vivo association. Because of its extended-release characteristics over an extended period of time, this quetiapine fumarate formulation appears to be a safer and better therapeutic choice for increased tolerance than traditional tablets.
Cite this article:
Yogesh S. Purkar, Rajendra K. Surawase. Formulation Development and Evaluation of Quetiapine fumarate Extended-Release tablet by using 23 Factorial designs. Research Journal of Pharmaceutical Dosage Forms and Technology. 2024; 16(4):301-8. doi: 10.52711/0975-4377.2024.00047
Cite(Electronic):
Yogesh S. Purkar, Rajendra K. Surawase. Formulation Development and Evaluation of Quetiapine fumarate Extended-Release tablet by using 23 Factorial designs. Research Journal of Pharmaceutical Dosage Forms and Technology. 2024; 16(4):301-8. doi: 10.52711/0975-4377.2024.00047 Available on: https://rjpdft.com/AbstractView.aspx?PID=2024-16-4-1
REFERENCE:
1. Sekhar KS, Nagabhushanam MV, Rao KS, Bhikshapathi D. Design, in vitro and in vivo evaluation of quetiapinefumarate extended-release tablets. Int J Pharm Bio Sci. 2013; 4(4): 578-95, DOI: 10.22376/ijpbs/ijpbs.2013.4.4.b578-595.
2. Mohapatra R, Senapati S, Sahoo C, Mishra S, Dinda A, Sahoo DK. In vitro release studies of extended-release matrix tablet formulations of highly soluble drugs. Res J Pharm Biol Chem Sci. 2013; 4: 116-28, DOI: 10.5958/j.0975-4393.2013.00015.1.
3. Venkateswarlu K, Nirosha M, Reddy BKK, Singh TH, Manasa S. Formulation and in vitro evaluation of quetiapinefumarate extended-release tablets using natural polymers. Latin Am J Pharm. 2017; 36(2): 392-8, DOI: 10.1016/ j.latamjpharm.2017.03.009.
4. Worrel JA, Marken PA, Beckman SE, Ruehter VL. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm. 2000; 57(3): 238-55, DOI: 10.1093/ajhp/57.3.238.
5. Sahu D, Rana AC. Formulation development of quetiapinefumarate SR matrix tablets. Der Pharm Sin. 2010; 1(1): 48-57, DOI: 10.1007/s12272-010-0406-1.
6. Bui K, Earley W, Nyberg S. Pharmacokinetic profile of the extended-release formulation of quetiapinefumarate (quetiapine XR): clinical implications. Curr Med Res Opin. 2013; 29(7): 813-25, DOI: 10.1185/03007995.2013.804628.
7. Kuksal A, Tiwary AK, Jain NK, Jain S. Formulation and in vitro, in vivo evaluation of extended-release matrix tablet of zidovudine: influence of combination of hydrophilic and hydrophobic matrix formers. AAPS PharmSciTech. 2006; 7DOI: 10.1208/pt070371.
8. Saleem A, Nasiri MI, Zaheer K, Anwar S, Ali T, Sarwar H, et al. Development and characterization of sustained-release matrix tablets of metformin hydrochloride using natural gums. LatAm J Pharm. 2018; 37(12): 2476-81, DOI: 10.1016/ j.latamjpharm.2018.11.009.
9. Gaikwad SS, Kshirsagar SJ. Application of tablet-in-tablet technique to design and characterize immediate and modified release tablets of timolol maleate. Heliyon. 2024; 10 DOI: 10.5958/0974-360X.2022.00653.9.
10. Pattana yak DP, Narayan UL, Dash AL, Mishra J, Mishra MK. Design and evaluation of an extended-release tablet dosage form of class-II drugs quetiapinefumarate. Int J Pharm. 2011; 2: 121-4, DOI: 10.4103/0975-1491.79100.
11. Krishna SR, Rao BM, Rao NS. Development of a simple and accurate reverse phase liquid chromatographic method for the determination of related substances and degradants of quetiapinefumarate bulk drug. Rasayan J Chem. 2008; 1(Suppl 3): 466-74, DOI: 10.22438/ijpbs.2013.3.4.17.
12. Shah UH, Patel B, Patel M. Formulation and evaluation of controlled release matrix tablet of diltiazem hydrochloride by using HPMC and guar gum as polymeric matrix material. Ars Pharm. 2012; 53: 16-20, DOI: 10.1046/j.1365-2125.2012.00499.x.
13. Nayak K, Sharma S, Mishra M. Formulation and evaluation of sustained release matrix tablets of glibenclamide. World J Pharm. 2016; 5: 974-88, DOI: 10.31531/wjpr.2016.1504.
14. Gaikwad SS, Kshirsagar SJ. Application of tablet-in-tablet technique to design and characterize immediate and modified release tablets of timolol maleate. Heliyon. 2024; DOI: 10.1016/j.heliyon.2024.10.e07609.
15. Saleem MU, Nasiri MI, Zaman SU, Khan N, Azeem M. Formulation development and characterization of cellulose/ polyacrylic acid–based polymers on the release of celecoxib from extended-release tablets. Journal of Polymer Research. 2020; 27: 1-7, DOI: 10.1007/s10965-020-02172-0.